Fennec Pharmaceuticals

Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development of sodium thiosulfate for the prevention of ototoxicity from cisplatin in pediatric cancer patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

~ PEDMARK is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized,  Non-metastatic Solid Tumors ~

Fennec Pharmaceuticals Announces Updated NCCN Clinical Practice Guidelines Recommend PEDMARK® (sodium thiosulfate injection) to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients

After two rejections, Fennec Pharmaceuticals finally secured FDA approval for its only asset, Pedmark.​ Additionally, the company secured non-dilutive capital to help initial commercialization efforts. While the market for Pedmark is limited, its critical use in the prevention of cisplatin-related hearing loss in pediatric patients assures market viability.

Fennec Pharmaceuticals: Ruminating The Prospects And Necessity Of A Sale

~ In September 2022, FDA Approved PEDMARK ® , the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Tumors ~

Fennec Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Business Update

After two CRLs, PEDMARK has finally been approved for preventing chemo-induced hearing loss in pediatric cancer patients. In addition to being both safe and effective, PEDMARK has not shown itself to interfere with the cancer-fighting properties of chemotherapy agents.

Fennec: Pedmark Approval Can Help Minimize Chemo-Induced Hearing Loss In Pediatric Cancer Patients

~ PEDMARK is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients ~

Fennec Pharmaceuticals Announces Commercial Availability of PEDMARK® (sodium thiosulfate injection) in the United States

~ Under the Terms of the Previously Announced Investment Agreement, $5 Million Already Funded Upon Initial Closing, Which Occurred on August 19, 2022, and $20 Million to be Funded Upon FDA Approval of PEDMARK® Which Occurred on September 20, 2022 ~

Fennec Pharmaceuticals Announces Second Closing of $20 Million Investment from Petrichor

Feneca Pharmaceuticals (FENC) receives FDA approval for Pedmark to reduce the risk of ototoxicity associated with cisplatin in pediatric patients with localized, non-metastatic solid tumors.

Feneca (FENC) Gets FDA Nod for Cancer-Related Hearing Loss Drug

~ PEDMARK® is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Solid Tumors ~

Fennec Pharmaceuticals Announces FDA Approval of PEDMARK® (Sodium Thiosulfate Injection)

PDUFA for Pedmark (sodium thiosulfate) in treating platinum chemotherapy-induced cytotoxicity (ear toxicity) in children is scheduled on September 23. The company resolved the issues raised in the second CRL within 3 months and announced the NDA acceptance in April this year.

Buying Fennec Pharma Ahead Of September PDUFA For Pedmark

~ Under the Terms of the Investment Agreement, $5 Million to be Funded on initial closing and $20 Million to be Funded Upon Potential FDA Approval of PEDMARK TM ~

Fennec Pharmaceuticals Closes First $5 Million Investment From Petrichor

~ PEDMARK TM FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for September 23, 2022 ~

Fennec Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Business Update

Fennec Pharmaceuticals Announces Up to $45 Million Investment From Petrichor

100% technical buy signals. 16 new highs and up 22.29% in the last month.

Fennec Pharmaceuticals - Biopharma

Here is how Adherex Technologies Inc. (FENC) and U.S. Physical Therapy (USPH) have performed compared to their sector so far this year.

Has Adherex Technologies (FENC) Outpaced Other Medical Stocks This Year?

The mean of analysts' price targets for Adherex Technologies Inc. (FENC) points to an 80.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Predict an 80% Upside in Adherex Technologies Inc. (FENC): Here's What You Should Know

~ FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for September 23, 2022 ~

Fennec Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update

The average of price targets set by Wall Street analysts indicates a potential upside of 91.9% in Adherex Technologies Inc. (FENC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Can Adherex Technologies Inc. (FENC) Climb 92% to Reach the Level Wall Street Analysts Expect?

~ Prescription Drug User Fee Act (PDUFA) target action date set for September 23, 2022 ~ ~ Prescription Drug User Fee Act (PDUFA) target action date set for September 23, 2022 ~

Fennec Pharmaceuticals Announces FDA Acceptance for Filing of New Drug Application Resubmission for PEDMARK™

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Fennec Pharmaceuticals Inc. ("Fennec" or the "Company") (NASDAQ: FENC) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Fennec securities between May 28, 2021, and November 26, 2021, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm's si

FENC Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Fennec Pharmaceuticals Inc. Investors of Class Action and Last Few Hours to Contact the Firm

New York, New York--(Newsfile Corp. - April 11, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) between May 28, 2021 and November 26, 2021, inclusive (the "Class Period"), of the important April 11, 2022 lead plaintiff deadline.SO WHAT: If you purchased Fennec Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of...

FENC FINAL DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages Fennec Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important April 11 Deadline in Securities Class Action - FENC

NEW YORK , April 11, 2022 /PRNewswire/ -- Attention Fennec Pharmaceuticals Inc. ("Fennec") (NASDAQ: FENC) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between May 28, 2021 and November 26, 2021. If you suffered a loss on your investment in Fennec, contact us about potential recovery by using the link below.

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Fennec Investors of a Lead Plaintiff Deadline of April 11, 2022

New York, New York--(Newsfile Corp. - April 10, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) between May 28, 2021 and November 26, 2021, inclusive (the "Class Period"), of the important April 11, 2022 lead plaintiff deadline.SO WHAT: If you purchased Fennec Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of pocket...

FENC FINAL DEADLINE TOMORROW: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Fennec Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important April 11 Deadline in Securities Class Action - FENC

New York, New York--(Newsfile Corp. - April 9, 2022) - Pomerantz LLP announces that a class action lawsuit has been filed against Fennec Pharmaceuticals Inc. ("Fennec" or the "Company") (NASDAQ: FENC) and certain of its officers. The class action, filed in the United States District Court for the Middle District of North Carolina, and docketed under 22-cv-00115, is on behalf of a class consisting of all persons and entities other than Defendants that...

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Fennec Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline - FENC

New York, New York--(Newsfile Corp. - April 8, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) between May 28, 2021 and November 26, 2021, inclusive (the "Class Period"), of the important April 11, 2022 lead plaintiff deadline.SO WHAT: If you purchased Fennec Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of...

FENC FINAL DEADLINE MONDAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Fennec Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important April 11 Deadline in Securities Class Action - FENC

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming April 11, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Fennec Pharmaceuticals Inc. (“Fennec” or the “Company”) (NASDAQ: FENC) securities between May 28, 2021 and November 26, 2021, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On November 29, 2021, before the market opened, Fenne

News for Fennec Pharmaceuticals Stock (FENC)